BSE Live
Feb 09, 16:01Prev. Close
2485.85
Open Price
2409.25
Bid Price (Qty.)
2511.00 (190)
Offer Price (Qty.)
2525.00 (5)
NSE Live
Feb 09, 15:59Prev. Close
2484.00
Open Price
2489.00
Bid Price (Qty.)
2516.20 (787)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of GlaxoSmithKline Pharmaceuticals (in Rs. Cr.) | Dec 04 | |
| 12 mths | ||
| EQUITIES AND LIABILITIES | ||
| SHAREHOLDER'S FUNDS | ||
| Equity Share Capital | 87.32 | |
| Total Share Capital | 87.32 | |
| Reserves and Surplus | 836.94 | |
| Total Reserves and Surplus | 836.94 | |
| Total Shareholders Funds | 924.26 | |
| NON-CURRENT LIABILITIES | ||
| Long Term Borrowings | 3.82 | |
| Deferred Tax Liabilities [Net] | 15.11 | |
| Other Long Term Liabilities | 0.00 | |
| Long Term Provisions | 0.00 | |
| Total Non-Current Liabilities | 18.93 | |
| CURRENT LIABILITIES | ||
| Short Term Borrowings | 0.03 | |
| Trade Payables | 204.09 | |
| Other Current Liabilities | 15.38 | |
| Short Term Provisions | 250.22 | |
| Total Current Liabilities | 469.72 | |
| Total Capital And Liabilities | 1,412.91 | |
| ASSETS | ||
| NON-CURRENT ASSETS | ||
| Tangible Assets | 69.80 | |
| Intangible Assets | 17.18 | |
| Capital Work-In-Progress | 4.51 | |
| Other Assets | 0.00 | |
| Fixed Assets | 91.49 | |
| Non-Current Investments | 776.83 | |
| Deferred Tax Assets [Net] | 59.97 | |
| Long Term Loans And Advances | 0.00 | |
| Other Non-Current Assets | 0.00 | |
| Total Non-Current Assets | 928.28 | |
| CURRENT ASSETS | ||
| Current Investments | 0.00 | |
| Inventories | 226.50 | |
| Trade Receivables | 76.06 | |
| Cash And Cash Equivalents | 63.38 | |
| Short Term Loans And Advances | 112.13 | |
| OtherCurrentAssets | 6.55 | |
| Total Current Assets | 484.63 | |
| Total Assets | 1,412.91 | |
| OTHER ADDITIONAL INFORMATION | ||
| CONTINGENT LIABILITIES, COMMITMENTS | ||
| Contingent Liabilities | 127.97 | |
| CIF VALUE OF IMPORTS | ||
| Raw Materials | 118.05 | |
| Stores, Spares And Loose Tools | 0.00 | |
| Trade/Other Goods | 0.00 | |
| Capital Goods | 0.17 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||
| Expenditure In Foreign Currency | 2.26 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||
| Dividend Remittance In Foreign Currency | 43.39 | |
| EARNINGS IN FOREIGN EXCHANGE | ||
| FOB Value Of Goods | 28.37 | |
| Other Earnings | 10.63 | |
| BONUS DETAILS | ||
| Bonus Equity Share Capital | 40.69 | |
| NON-CURRENT INVESTMENTS | ||
| Non-Current Investments Quoted Market Value | 510.13 | |
| Non-Current Investments Unquoted Book Value | 327.25 | |
| CURRENT INVESTMENTS | ||
| Current Investments Quoted Market Value | -- | |
| Current Investments Unquoted Book Value | -- |
12.11.2025
GlaxoSmithKline Standalone September 2025 Net Sales at Rs 973.63 crore, down 2.64% Y-o-Y
07.11.2025
GlaxoSmithKline Consolidated September 2025 Net Sales at Rs 979.94 crore, down 3.05% Y-o-Y
12.08.2025
GlaxoSmithKline Consolidated June 2025 Net Sales at Rs 805.17 crore, down 1.16% Y-o-Y
01.08.2025
GlaxoSmithKline Standalone June 2025 Net Sales at Rs 804.83 crore, down 0.76% Y-o-Y